Karyopharm Therapeutics (KPTI) Shares Outstanding (Diluted Average) (2020 - 2025)
Karyopharm Therapeutics (KPTI) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $8470.0 as the latest value for Q1 2025.
- For the quarter ending Q1 2025, Shares Outstanding (Diluted Average) rose 10.0% year-over-year to $8470.0, compared with a TTM value of $8470.0 through Mar 2025, up 10.0%, and an annual FY2023 reading of $114.2 million, up 39.51% over the prior year.
- Shares Outstanding (Diluted Average) was $8470.0 for Q1 2025 at Karyopharm Therapeutics, down from $154.4 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $154.4 million in Q2 2024 and bottomed at $7700.0 in Q1 2024.
- Average Shares Outstanding (Diluted Average) over 5 years is $82.5 million, with a median of $79.4 million recorded in 2022.
- The sharpest move saw Shares Outstanding (Diluted Average) surged 46.29% in 2023, then tumbled 99.99% in 2024.
- Year by year, Shares Outstanding (Diluted Average) stood at $75.2 million in 2021, then rose by 8.84% to $81.9 million in 2022, then surged by 39.51% to $114.2 million in 2023, then surged by 35.2% to $154.4 million in 2024, then tumbled by 99.99% to $8470.0 in 2025.
- Business Quant data shows Shares Outstanding (Diluted Average) for KPTI at $8470.0 in Q1 2025, $154.4 million in Q2 2024, and $7700.0 in Q1 2024.